Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181433 | 0.97 | HDAC4 (0.33) | PDE10AFOLH1TAS1R3TAS1R1SYK | |
| SCHEMBL18181115 | 0.94 | PDE10A (0.33) | PDE10ATAS1R3TAS1R1SYKPYGL | |
| SCHEMBL16670170 | 0.93 | FFAR1 (0.34) | PDE10ATAS1R3TAS1R1SYKPYGL | |
| SCHEMBL18180300 | 0.92 | NOS2 (0.36) | PDE10ATAS1R3TAS1R1SYKPYGL | |
| SCHEMBL21992753 | 0.92 | SYK (0.32) | PDE10ATAS1R3TAS1R1SYKPYGL | |
| SCHEMBL18180352 | 0.91 | PDE10A (0.31) | PDE10A | |
| SCHEMBL18181067 | 0.91 | SYK (0.31) | PDE10ASYKKDM1AMAOA | |
| SCHEMBL20782939 | 0.91 | PDE10A (0.31) | PDE10A | |
| SCHEMBL18181173 | 0.91 | PDE10A (0.31) | PDE10A | |
| SCHEMBL18179993 | 0.91 | TAS1R3 (0.34) | PDE10ATAS1R3TAS1R1SYKPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | PDE10A 2805/4885FOLH1 3511/4885TAS1R3 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.